Technical Analysis for NEOS - Neos Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 2.92 6.57% 0.18
NEOS closed up 6.57 percent on Tuesday, March 19, 2019, on 1.67 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical NEOS trend table...

Date Alert Name Type % Chg
Mar 19 New Uptrend Bullish 0.00%
Mar 19 Pocket Pivot Bullish Swing Setup 0.00%
Mar 19 Upper Bollinger Band Walk Strength 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 19 Above Upper BB Strength 0.00%
Mar 19 Overbought Stochastic Strength 0.00%
Mar 19 Up 3 Days in a Row Strength 0.00%
Mar 19 Up 4 Days in a Row Strength 0.00%
Mar 19 Up 5 Days in a Row Strength 0.00%
Mar 19 Upper Bollinger Band Touch Strength 0.00%

Older signals for NEOS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie, Texas.
Pharmaceutical Drugs Pharmacology Euphoriants Psychoactive Drugs Attention Deficit Hyperactivity Disorder Cough Hydrocodone Adhd Allergies Amphetamine Drug Delivery Technologies Methylphenidate Nootropics Treatment Of Attention Deficit Hyperactivity Disorder Phenethylamines Stimulants
Is NEOS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.2
52 Week Low 1.4
Average Volume 332,249
200-Day Moving Average 3.9503
50-Day Moving Average 2.266
20-Day Moving Average 2.366
10-Day Moving Average 2.38
Average True Range 0.2209
ADX 26.17
+DI 30.6546
-DI 12.0173
Chandelier Exit (Long, 3 ATRs ) 2.3273
Chandelier Exit (Short, 3 ATRs ) 2.5827
Upper Bollinger Band 2.811
Lower Bollinger Band 1.921
Percent B (%b) 1.12
BandWidth 37.61623
MACD Line 0.1119
MACD Signal Line 0.0454
MACD Histogram 0.0665
Fundamentals Value
Market Cap 81.99 Million
Num Shares 28.1 Million
EPS -4.30
Price-to-Earnings (P/E) Ratio -0.68
Price-to-Sales 18.06
Price-to-Book 10.86
PEG Ratio -0.04
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.36
Resistance 3 (R3) 3.33 3.16 3.28
Resistance 2 (R2) 3.16 3.05 3.17 3.26
Resistance 1 (R1) 3.04 2.98 3.10 3.07 3.23
Pivot Point 2.87 2.87 2.90 2.88 2.87
Support 1 (S1) 2.75 2.76 2.81 2.78 2.61
Support 2 (S2) 2.58 2.69 2.59 2.58
Support 3 (S3) 2.46 2.58 2.56
Support 4 (S4) 2.49